The Lithuanian government is focused on life science innovation as a cornerstone for promoting competitiveness and growth of the country. Key areas include: biotechnology, pharmaceuticals, medical devices, and related fields. The Lithuanian biotech sector’s sales have grown by about 22 percent each year for the last five years. The Lithuanian government has increased funding of biotech research and research facilities, accelerators, and new programs to sustain industry growth. The country also has an established and evolving regulatory process for the clinical evaluation, approval, and pricing of biotechnology and health care products. This panel will address some of these key business  and regulatory areas that are relevant to these policies and processes, their impact, and possible directions forward.


Learning Objectives:

  • Gain insight into Lithuanian life sciences, changes in policies, infrastructure, industry and innovation
  • Review unmet needs and business opportunities for clinical and regulatory partnerships and collaborations
  • Discover HORIZON 2020 - the €80 billion EU Framework Programme for R&I and how you can be part of it

Ability Level: Intermediate

Session ID: 1949

myBIO Chatter

Speakers (3)

contact_9790 Martin Berardi Corporate Vice President Moog Inc.
contact_9879 Milda Darguzaite Managing Director Invest Lithuania
contact_9878 Arunas Karlonas Director Agency for Science, Innovation and Technology

Moderators (1)

contact_1113 Gary Keller President & CEO Xomix, Ltd

Who's Attending (2)

See all